X4 Pharma slips on launching stock offering

X4 Pharmaceuticals

23/10/2025 21:20

** Shares of X4 Pharmaceuticals XFOR.O down 2.9% at $3 in extended trading as it looks to raise capital

** Boston-based firm commences offering of stock and pre-funded warrants; deal size not disclosed

** Co plans to use net offering proceeds to fund Phase 3 development of mavorixafor in certain chronic neutropenic disorders, as well as capex and other purposes

** Chronic neutropenia is a condition with low levels of neutrophils, a type of white blood cell that fights infection

** Leerink, Stifel and Guggenheim are joint bookrunning managers for offering

** XFOR has 11.4 mln shares outstanding for $35 mln market cap

** XFOR shares finished down 0.3% at $3.09 on Thurs, down 86% YTD

** All 5 analysts covering the stock are bullish with $9 median PT, according to LSEG data

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))